Comparative Pharmacology
Head-to-head clinical analysis: PARADIONE versus ZONISADE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARADIONE versus ZONISADE.
PARADIONE vs ZONISADE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Zonisamide is a sulfonamide anticonvulsant. Its precise mechanism of action is unknown, but it is believed to inhibit voltage-sensitive sodium channels and reduce T-type calcium currents, thereby stabilizing neuronal membranes and suppressing neuronal hypersynchronization. It may also modulate GABA and glutamate neurotransmission.
100 mg orally three times daily; maximum 600 mg/day.
100-200 mg orally every 8 hours; maximum 600 mg/day.
None Documented
None Documented
12-24 hours (terminal); prolonged in renal impairment
Terminal elimination half-life: 63-69 hours in adults; allows once-daily dosing; steady-state achieved in 14-21 days
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Renal: approximately 62% (35% unchanged, 27% as glucuronide conjugate); fecal: 3%; biliary: negligible
Category C
Category C
Anticonvulsant
Anticonvulsant